Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the “Artisan Mid Cap Value Fund”. A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund’s Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index’s 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund’s top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
“Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative assumptions for free cash flow.”
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 49 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the first quarter, up from 41 in the previous quarter. While we acknowledge the risk and potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ICON Public Limited Company (NASDAQ:ICLR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered ICON Public Limited Company (NASDAQ:ICLR) and shared Greenskeeper Asset Management’s views on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
